Accumulating evidence indicates that desaturases, including stearoyl-CoA desaturases-1 (SCD1), have emerged as key players in the regulation of metabolic and signaling pathways that support the biochemical and biological phenotype of cancer cells, and targeting SCD1 has the potential to develop new cancer therapeutics [21,22]. This evidence concerns the gene SCD and cancer.